Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions often present in a comparison of the U.S. and European markets.
The development of the U.S. biosimilars market often is cast in the shadow of Europe’s earlier entry into the arena. A decade after the United States established its own biosimilars pathway, the paper discusses that we are past time to move beyond this outdated perception and consider what the United States can learn from Europe’s longer — but not necessarily more successful — experience with biosimilars.
In this paper, MGA addresses several misconceptions often present in a comparison of the U.S. and European markets and identifies both cautionary lessons for the U.S. biosimilars industry and lessons the United States would do well to follow.
